BioMark Diagnostics Inc. (BUX.CN)
CAD 0.2
(0.0%)
CAD 0.2
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.42 Million CAD | 22.52% |
| 2022 | -1.84 Million CAD | -26.71% |
| 2021 | -1.45 Million CAD | -32.87% |
| 2020 | -1.09 Million CAD | 9.96% |
| 2019 | -1.21 Million CAD | -122.74% |
| 2018 | -545.61 Thousand CAD | 24.92% |
| 2017 | -726.74 Thousand CAD | -1.58% |
| 2016 | -715.42 Thousand CAD | 49.01% |
| 2015 | -1.4 Million CAD | 51.2% |
| 2014 | -2.87 Million CAD | -1488.52% |
| 2013 | -180.99 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -623.27 Thousand CAD | -59.28% |
| 2023 FY | -1.42 Million CAD | 22.52% |
| 2023 Q2 | -210.46 Thousand CAD | 49.75% |
| 2023 Q1 | -418.85 Thousand CAD | 16.48% |
| 2023 Q3 | -406.76 Thousand CAD | -93.27% |
| 2023 Q4 | -391.3 Thousand CAD | 3.8% |
| 2022 Q1 | -419.14 Thousand CAD | 42.57% |
| 2022 FY | -1.84 Million CAD | -26.71% |
| 2022 Q4 | -501.5 Thousand CAD | -27.38% |
| 2022 Q3 | -393.69 Thousand CAD | 25.42% |
| 2022 Q2 | -527.88 Thousand CAD | -25.94% |
| 2021 Q2 | -178.39 Thousand CAD | 38.22% |
| 2021 FY | -1.45 Million CAD | -32.87% |
| 2021 Q4 | -729.87 Thousand CAD | -163.78% |
| 2021 Q3 | -276.69 Thousand CAD | -55.1% |
| 2021 Q1 | -288.75 Thousand CAD | 50.55% |
| 2020 FY | -1.09 Million CAD | 9.96% |
| 2020 Q4 | -583.97 Thousand CAD | -200.73% |
| 2020 Q2 | -187.45 Thousand CAD | -45.8% |
| 2020 Q3 | -194.18 Thousand CAD | -3.59% |
| 2020 Q1 | -128.57 Thousand CAD | 55.03% |
| 2019 Q3 | -672.89 Thousand CAD | -395.04% |
| 2019 Q4 | -285.9 Thousand CAD | 57.51% |
| 2019 FY | -1.21 Million CAD | -122.74% |
| 2019 Q1 | -120.55 Thousand CAD | 2.16% |
| 2019 Q2 | -135.92 Thousand CAD | -12.75% |
| 2018 FY | -545.61 Thousand CAD | 24.92% |
| 2018 Q4 | -123.21 Thousand CAD | 26.95% |
| 2018 Q3 | -168.66 Thousand CAD | -5.05% |
| 2018 Q1 | -110.91 Thousand CAD | 24.82% |
| 2018 Q2 | -160.55 Thousand CAD | -44.76% |
| 2017 Q3 | -176.37 Thousand CAD | 19.25% |
| 2017 FY | -726.74 Thousand CAD | -1.58% |
| 2017 Q1 | -184.41 Thousand CAD | 22.46% |
| 2017 Q2 | -218.42 Thousand CAD | -18.44% |
| 2017 Q4 | -147.53 Thousand CAD | 16.35% |
| 2016 Q1 | -215.53 Thousand CAD | 69.24% |
| 2016 FY | -715.42 Thousand CAD | 49.01% |
| 2016 Q4 | -237.82 Thousand CAD | -112.81% |
| 2016 Q3 | -111.75 Thousand CAD | 25.65% |
| 2016 Q2 | -150.3 Thousand CAD | 30.26% |
| 2015 FY | -1.4 Million CAD | 51.2% |
| 2015 Q1 | -209.29 Thousand CAD | 70.36% |
| 2015 Q3 | -260.89 Thousand CAD | -12.36% |
| 2015 Q4 | -700.74 Thousand CAD | -168.6% |
| 2015 Q2 | -232.18 Thousand CAD | -10.94% |
| 2014 FY | -2.87 Million CAD | -1488.52% |
| 2014 Q3 | -2.05 Million CAD | -3889.1% |
| 2014 Q4 | -706.11 Thousand CAD | 65.57% |
| 2014 Q2 | -51.4 Thousand CAD | 22.11% |
| 2014 Q1 | -65.99 Thousand CAD | 0.0% |
| 2013 FY | -180.99 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Izotropic Corporation | -1.56 Million CAD | 8.58% |
| Sona Nanotech Inc. | -2.49 Million CAD | 42.897% |